Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

New Delhi, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The global pharma & biotech CRM software market was valued at US$ 7.21 billion IN 2024 and is projected to reach US$ 20.0 by 2033 at a CAGR of 15.2% during ...

According to recent reports, the skincare market in the UK reached an estimated £1.782 billion in 2023, which is expected to ...

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company with a market capitalization of $40.39 million, has announced a strategic partnership with Zina ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...

SURPASS-ET Clinical Results Clinical Trial Overview SURPASS-ET (NCT04285086 ... compared to a reduction from 39.7% to 37.3% (-2.4% change) in the Anagrelide group. These results suggest that ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9.Stay Ahead of the ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space ... For one, Lilly in early December shared the results of a head-to-head trial pitting Zepbound against Wegovy, in which ...

Spain — one of Europe's fastest growing economies, according to the OECD — is set to publish import and export figures on ...

1 According to Lilly, the study showed that Zepbound resulted in an average weight loss of 20.2%, which was significantly higher than ... Nearly half of clinical trial patients saw such improvements ...

"We will conduct Phase 3 clinical trials targeting head and neck cancer and colorectal cancer patients with EGFR mutation." Gwachon National Science Museum reopens Hall of Evolution on 28th The ...